ArticleCleaning Up Evidence-Based PsychopharmacologyOsser, David N. MDEditor(s): Janicak, Philip G. MD Author Information Editor Dr. Osser is Associate Professor of Psychiatry, Harvard Medical School, Boston, MA;150 Winding River Road, Needham, MA 02492; E-mail: [email protected]. The author has disclosed that he has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. All ftafs in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Acknowledgments. The author thanks the following individuals for their thoughtful reading and suggestions: James Evans, MD, Eliot M. Gelwan, MD, Nassir Ghaemi, MD, and Michael P. Krupa, EdD. The author has disclosed that the use of lamotrigine for treatment of acute bipolar depression as discussed in this article has not been approved by the U.S. Food and Drug Administration. This continuing education activity is intended for psychiatrists and other health care professionals with an interest in psychotropic drug therapy. Psychopharm Review: March 2008 - Volume 43 - Issue 3 - p 19-25 doi: 10.1097/01.IDT.0000311517.65367.cf Buy Metrics Abstract Learning Objectives After reading this article, the practitioner should be able to: Describe the likelihood that industry-sponsored continuing medical education will contain biases, both obvious and subtle. Recall the extent to which academic psychopharmacology is “owned” yb pharmaceutical companies. Explain the importance of joining a psychopharmacology journal club and increasing the practitioner's skills in reading the literature. © 2008 Lippincott Williams & Wilkins, Inc.